 Antineoplastic Agents, Phytogenic
"Antineoplastic Agents, Phytogenic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.
| Descriptor ID |
D000972
|
| MeSH Number(s) |
D27.505.954.248.179
|
| Concept/Terms |
Antineoplastic Agents, Phytogenic- Antineoplastic Agents, Phytogenic
- Agents, Phytogenic Antineoplastic
- Phytogenic Antineoplastic Agents
- Antineoplastics, Phytogenic
- Phytogenic Antineoplastics
- Antineoplastics, Botanical
- Botanical Antineoplastics
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Phytogenic".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Phytogenic".
This graph shows the total number of publications written about "Antineoplastic Agents, Phytogenic" by people in this website by year, and whether "Antineoplastic Agents, Phytogenic" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 3 | 0 | 3 | | 1996 | 4 | 1 | 5 | | 1997 | 1 | 0 | 1 | | 1998 | 0 | 1 | 1 | | 1999 | 1 | 1 | 2 | | 2000 | 1 | 1 | 2 | | 2001 | 1 | 2 | 3 | | 2002 | 2 | 2 | 4 | | 2003 | 3 | 2 | 5 | | 2004 | 3 | 2 | 5 | | 2005 | 7 | 1 | 8 | | 2006 | 7 | 5 | 12 | | 2007 | 7 | 3 | 10 | | 2008 | 3 | 1 | 4 | | 2009 | 4 | 1 | 5 | | 2010 | 6 | 1 | 7 | | 2011 | 1 | 5 | 6 | | 2012 | 4 | 3 | 7 | | 2013 | 4 | 2 | 6 | | 2014 | 4 | 2 | 6 | | 2015 | 1 | 1 | 2 | | 2016 | 3 | 4 | 7 | | 2017 | 4 | 2 | 6 | | 2018 | 4 | 0 | 4 | | 2019 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Antineoplastic Agents, Phytogenic" by people in Profiles.
-
Rigby C, Deep G, Jain A, Orlicky DJ, Agarwal C, Agarwal R. Silibinin inhibits ultraviolet B radiation-induced mast cells recruitment and bone morphogenetic protein 2 expression in the skin at early stages in Ptch(+/-) mouse model of basal cell carcinoma. Mol Carcinog. 2019 07; 58(7):1260-1271.
-
Tyagi A, Kumar S, Raina K, Wempe MF, Maroni PD, Agarwal R, Agarwal C. Differential effect of grape seed extract and its active constituent procyanidin B2 3,3?-di-O-gallate against prostate cancer stem cells. Mol Carcinog. 2019 07; 58(7):1105-1117.
-
Rose PG, Java JJ, Salani R, Geller MA, Secord AA, Tewari KS, Bender DP, Mutch DG, Friedlander ML, Van Le L, Method MW, Hamilton CA, Lee RB, Wenham RM, Guntupalli SR, Markman M, Muggia FM, Armstrong DK, Bookman MA, Burger RA, Copeland LJ. Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma. Obstet Gynecol. 2019 02; 133(2):245-254.
-
Ghoreishi Z, Keshavarz S, Asghari Jafarabadi M, Fathifar Z, Goodman KA, Esfahani A. Risk factors for paclitaxel-induced peripheral neuropathy in patients with breast cancer. BMC Cancer. 2018 Oct 05; 18(1):958.
-
Kucharczyk K, Weiss M, Jastrzebska K, Luczak M, Ptak A, Kozak M, Mackiewicz A, Dams-Kozlowska H. Bioengineering the spider silk sequence to modify its affinity for drugs. Int J Nanomedicine. 2018; 13:4247-4261.
-
Hosseinipour MC, Kang M, Krown SE, Bukuru A, Umbleja T, Martin JN, Orem J, Godfrey C, Hoagland B, Mwelase N, Langat D, Nyirenda M, MacRae J, Borok M, Samaneka W, Moses A, Mngqbisa R, Busakhala N, Martínez-Maza O, Ambinder R, Dittmer DP, Nokta M, Campbell TB. As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial. Clin Infect Dis. 2018 07 02; 67(2):251-260.
-
Dhar D, Deep G, Kumar S, Wempe MF, Raina K, Agarwal C, Agarwal R. Bitter melon juice exerts its efficacy against pancreatic cancer via targeting both bulk and cancer stem cells. Mol Carcinog. 2018 09; 57(9):1166-1180.
-
Manley PE, Trippett T, Smith AA, Macy ME, Leary SES, Boklan J, Cohen KJ, Goldman S, Kilburn LB, Dhall G, Devin J, Herzog CE, Partap S, Fauchet F, Badreddine E, Bernard JP, Chi SN. A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system. Pediatr Blood Cancer. 2018 09; 65(9):e27217.
-
Smolik S, Arland L, Hensley MA, Schissel D, Shepperd B, Thomas K, Rodgers C. Assessment Tools for Peripheral Neuropathy in Pediatric Oncology: A Systematic Review From the Children's Oncology Group. J Pediatr Oncol Nurs. 2018 Jul/Aug; 35(4):267-275.
-
Wainberg ZA, Alsina M, Soares HP, Braña I, Britten CD, Del Conte G, Ezeh P, Houk B, Kern KA, Leong S, Pathan N, Pierce KJ, Siu LL, Vermette J, Tabernero J. A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer. Target Oncol. 2017 Dec; 12(6):775-785.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|